Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17148179 | 1.00 | CA1 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL109451 | 0.89 | CA1 (0.61) | CA1CA2CA12CA9CA14 | |
| SCHEMBL7165380 | 0.85 | KMT2A (0.49) | CA1CA2CA12CA9CA14 | |
| Hydrazine SCHEMBL10771056 | 0.85 | CA12 (0.62) | CA1CA2CA12CA9CA14 | |
| SCHEMBL6350965 | 0.83 | CA12 (0.71) | CA1CA2CA12CA9CA14 | |
| SCHEMBL4532351 | 0.83 | ELANE (0.60) | CA1CA2CA12CA9CA14 | |
| SCHEMBL30823609 | 0.82 | RAB9A (0.45) | CA1CA2CA12CA9CA14 | |
| SCHEMBL12832686 | 0.81 | ADRB2 (0.47) | RAB9AMEN1KMT2ANPC1MAPT | |
| SCHEMBL4517212 | 0.81 | CA12 (0.54) | CA1CA2CA12CA9CA14 | |
| SCHEMBL7346788 | 0.81 | CA1 (0.59) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109535081-A | A kind of preparation method of Flubendazole impurity E | 江苏宝众宝达药业有限公司 | 2019-03-29 | — | — | CN | claimed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12521393-B2 | Cytotoxicity targeting chimeras for CCR2-expressing cells | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-13 | — | — | US | disclosed |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4662211-A1 | G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) DEGRADATION COMPOUNDS AND USE THEREOF | Nanjing Huanbo Biotechnology Co., Ltd. (CN) | 2025-12-17 | — | — | EP | disclosed |
| EP-4656642-A1 | ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF | GAN & LEE PHARM CO., LTD (CN) | 2025-12-03 | — | — | EP | disclosed |
| CN-1039714-C | Substituted indole, azaindole and tetrahydro-1H-pyrrol pyrrolo [2,3-c] pyridin-7-one derivatives | SYTEX U S A INC (US) | 1998-09-09 | — | — | CN | disclosed |
| US-5795893-A | Fibrinogen receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0801650-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0801650-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-22 | — | — | EP | disclosed |
| WO-1996019475-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-06-27 | — | — | WO | disclosed |
| EP-0640080-A1 | SUBSTITUTED INDOLES AND AZAINDOLES AS ANGIOTENSIN II ANTAGONISTS. | SYNTEX INC (US) | 1995-03-01 | — | — | EP | disclosed |
| US-5380739-A | Angiotensin II antagonists | SYNTEX (U.S.A.) INC. (US) | 1995-01-10 | — | — | US | disclosed |
| WO-1993023391-A1 | SUBSTITUTED INDOLES AND AZAINDOLES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| CN-1078469-A | Substituted indole, the assorted indoles of ammonia and tetrahydro-1 H-pyrrolo be [2,3-c] pyridin-7-one derivatives also | SYTEX A INC (US) | 1993-11-17 | — | — | CN | disclosed |
| EP-0284413-A2 | Derivative of a fibrinolytic enzyme | BEECHAM GROUP PLC (GB) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, NR5A1, KLK3 | CA1 691/4885CA2 355/4885CA12 254/4885 |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | CA1 3061/4885CA2 2974/4885CA12 1835/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | CA1 3404/4885CA2 2924/4885CA12 2742/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | CA1 436/4885CA2 323/4885CA12 1371/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | CA1 2045/4885CA2 2413/4885CA12 3603/4885 |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | CA1 291/4885CA2 1122/4885CA12 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.